Prosecution Insights
Last updated: August 18, 2026

Examiner: WARD, PAUL V

Tech Center 1600 • Art Units: 1622 1624

This examiner grants 83% of resolved cases

Performance Statistics

83.1%
Allow Rate
+23.1% vs TC avg
1,720
Total Applications
-11.9%
Interview Lift
856
Avg Prosecution Days
Based on 1699 resolved cases, 2023–2026

Rejection Statute Breakdown

5.6%
§101 Eligibility
18.6%
§102 Novelty
20.4%
§103 Obviousness
42.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18277522 COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES Non-Final OA The Regents of the University of California
17921051 Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation Final Rejection Emory University
19225710 INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS Non-Final OA Bayer Aktiengesellschaft
18559805 COMPOSITION COMPRISING AHAS AND/OR BHAS WHICH IS STABILIZED BY A COMBINATION OF MONOALKYL OR DIALKYL ISOSORBIDE, POLYETHYLENE GLYCOL-POLYPROPYLENE GLYCOL ETHER AND TWO HYDROGENATED OR NON-HYDROGENATED POLYOXYETHYLENATED PLANT OILS Non-Final OA L'OREAL
18842728 PCNA INHIBITORS AND USES THEREOF Non-Final OA CITY OF HOPE

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month